PD-1, PD-L1 inhibition effective against metastatic urothelial carcinoma
Inhibitors against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) provide comparable survival benefits in patients with platinum-resistant metastatic urothelial cancer, reports a recent meta-analysis.
PD-1, PD-L1 inhibition effective against metastatic urothelial carcinoma
27 Nov 2019